This study examines the cognitive impairment profile of schizophrenia patients during maintenance electroconvulsive therapy (M-ECT). Ten schizophrenia patients treated with M-ECT and ten control patients matched for diagnosis, sex, and age who had never been treated with ECT were assessed with a comprehensive neuropsychological battery. M-ECT patients did not show a higher level of memory, attention, or frontal function impairment than the control group. The absence of additional memory dysfunction may favor the functional adaptation of these patients during M-ECT.
Maintenance electroconvulsive therapy is an effective treatment for some drug-resistant schizophrenia patients (Kales et al. 1999; Chanpattana 2000; Chanpattana et al. 2000; Stevens et al. 2001) . When added to antipsychotic medications, ECT for treatment-refractory schizophrenia has had favorable results (Kales et al. 1999; Conley and Kelly 2001; Hirose et al. 2001) .
Although M-ECT has been used increasingly in treatment-refractory schizophrenia patients, studies on the cognitive risk of continuing ECT are few. Studies concerning M-ECT in schizophrenia focus on clinical efficacy and only include global cognitive screening such as the Mini-Mental State Examination (MMSE; Chanpattana 1998; Chanpattana et al. 1999) . Consistent data about adverse neuropsychological effects of ECT are based on acute courses of treatment, frequently in depressed patients. In this case, most reports have shown transient memory dysfunction that wears off 3 to 6 months after completing treatment (Rami-Gonzalez et al. 2001 ). Other cognitive functions such as attention or frontal functions have been little studied, but they seem less affected by an ECT course than memory (Calev et al. 1995) . The aim of this study was to determine the cognitive impairment profile in schizophrenia patients receiving M-ECT.
Method
Ten drug-resistant patients (according to Kane et al. 1988) who met a Diagnostic and Statistical Manual of Mental Disorders-TV (DSM-IV; American Psychiatric Association 1994) diagnosis for schizophrenia (eight paranoid subtype and two undifferentiated) and participated in the M-ECT program were selected from the Clinical Institute of Psychiatry and Psychology at the Hospital Clinic, Barcelona, Spain. All patients had presented associated affective, catatonic, or violence symptoms, and they had a good response to a combination of ECT and antipsychotic medications.
According to the clinical protocol, the frequency of sessions was adapted to the needs of each patient. At the time of the study, the mean intersession interval in the sample was 37 days (standard deviation [SD] = 12.5; range 30 to 60 days). The mean of total previous ECT sessions was 27.2, and the mean time of M-ECT was 13.5 months. Most patients (seven out of ten) finished their acute ECT course 6 months before assessment; for three patients, 4 months had passed since the ECT course. Patients were treated with the standard bifrontotemporal electrode placement with a customized MECTA spectrum device. Atropine, succinylcholine, and thiobarbital were the anesthetic medications used.
The control group consisted of ten schizophrenia patients who had never received ECT. They were matched with the ECT patients for age, sex, years of education, and DSM-FV diagnosis. Eight patients met DSM-FV criteria for paranoid schizophrenia and two for undifferentiated schizophrenia. Patients in both groups were treated with an atypical antipsychotic drug (table 1) Send reprint requests to Dr. M. Bernardo, Servicio de Psiquiatrfa, Hospital CKnic, Calle Villarroel, 170 Barcelona 08036, Spain.
Written informed consent was obtained from all patients and controls after the procedures had been fully explained. Cognitive assessment was performed on all subjects. ECT patients were assessed on the day of the ECT session, before treatment, to guarantee maximum intercession time. To avoid symptomatology interference, at the moment of neuropsychological assessment all patients underwent a Hamilton Rating Scale for Depression (HRS-D < 8) assessment (Hamilton 1967 ) and had been free of positive symptoms for at least 3 months before the study, as assessed by two clinicians. The cognitive battery included an evaluation of global cognitive function by MMSE (Folstein 1975) . The Logical Memory subtest of the Wechsler Memory Scale (Russell 1987 ) and the Total Learning subtest of the Rey Auditory Verbal Learning Test (RAVLT; Rey 1964) were used to assess encoding of new information or short-term memory, and Delayed Logical Memory (Russell 1987) and verbal recall in delay on the RAVLT were used to assess long-term memory. The Digits Forward subtest of the Wechsler Adult Intelligence Scale (WAIS; Wechsler 1990) was used to assess selective attention, and Part A of the Trail Making Test (Army Individual Test Battery 1944) was used to assess simple motor velocity and attention. The Digit Symbol-Coding subtest from the WAIS-HI was used to determine visuomotor speed. Frontal functions were assessed with the Trail Making Test, Part B; the Tower of Hanoi task (Goldberg et al.1990) ; and the Digits Backward test (Wechsler 1990) , measuring mental flexibility, planning, and working memory, respectively. Verbal fluency, measured by the FAS-test (Borgowski et al. 1967) , was also used as an indication of frontal function (table 2) 
Discussion
No differences in either years of disease duration or number of psychotic episodes were found between groups, and no significant differences were detected between the groups in age, sex or years of schooling.
No significant differences in any cognitive measure were observed between M-ECT patients and the control group. The results of all tests were very similar in the two groups. No significant correlation was found between numbers of previous ECT treatments and any cognitive measure. The dispersion graph was analyzed visually, and no significant outliers were found (table 3) .
Our results show that schizophrenia patients during M-ECT could not be distinguished from matched patients in any of the cognitive measures. Very similar results were obtained in both groups regarding memory, attention, and frontal functions. According to clinical norms (Lezak 1995; Spreen and Strauss 1998) , both groups obtained the same cognitive profile associated with schizophrenia disorder: short-term memory and frontal function test scores below the normal range and long-term memory scores in normal range.
Memory impairment is the main neuropsychological problem associated with acute ECT. Long-term memory is clearly deficient after a course of ECT (Frith et al. 1983; Hasse-Sander et al. 1998) and is significantly deficient for 3 months after an acute treatment. Although the precise mechanism of memory dysfunction remains unclear, some neurobiological bases involving long-term potentiation processes have been proposed (Rami-Gonzdlez et al. 2001) . The absence of this dysfunction in our sample could be explained by the long interval between M-ECT sessions. This long period may have played a significant role in recovering neurobiological processes implicated in memory dysfunction after an ECT course.
Very little information is available on the effects of ECT on nonmemory functions (Calev et al. 1995) . Studies have reported either no effects (Small et al. 1986; Lawson et al. 1990) or fewer effects than on memory (Taylor et al. 1985 , Calev et al. 1991 . In the present study, no additional frontal dysfunction was found, contrary to our results in a previous study based on M-ECT in elderly depressive patients (Rami-Gonzdlez et al. 2003) . The number of ECT treatments and total time in M-ECT was higher in our depressive sample than in our schizophrenia sample. It would be interesting to perform longitudinal studies in schizophrenia patients who have received a greater number of ECTs to rule out an additional frontal dysfunction in this group. Although this preliminary study found that M-ECT schizophrenia patients did not present a higher number of cognitive deficits than control patients, these results should be interpreted with caution because of the study's limitations. In particular, the low number of subjects restricted the likelihood of establishing differences between groups owing to lack of statistical power. Confirming these results, especially the normal long-term memory results, with ambulatory electroconvulsive therapy is essential for optimal functional adaptation of schizophrenia patients during this treatment. Moreover, the absence of cognitive impairment associated with M-ECT in schizophrenia patients might facilitate the inclusion of patients in M-ECT programs.
